Eosinophilic Dermatoses

Published on 05/03/2015 by admin

Filed under Dermatology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2133 times

20

Eosinophilic Dermatoses

As with the group of disorders known as neutrophilic dermatoses, there is significant overlap in the cutaneous findings of entities where eosinophils play a role – from papular urticaria triggered by arthropod bites to Wells’ syndrome and hypereosinophilic syndrome (Fig. 20.1; Table 20.1). The exception is granuloma faciale, which has a more specific presentation.

Table 20.1

Other disorders where eosinophils play a role (in addition to those listed in Fig. 20.1).

• Scabies – see Chapter 71

• Parasitic infections (e.g. larva migrans, onchocerciasis, schistosomiasis, strongyloidiasis)

• Seabather’s eruption – after ocean swimming, pruritic papules in distribution of swimsuit; due to larvae of either jellyfish (Linuche unguiculata) or sea anemones (Edwardsiella lineata)

• Pruritic papular eruption of HIV disease – nonfollicular pruritic papules

• Polymorphic eruption of pregnancy (also referred to as PUPPP) – urticarial plaques with involvement of striae and periumbilicial sparing; pregnant women

• Pemphigoid gestationis – urticarial plaques and vesicles similar to bullous pemphigoid; pregnant women

• Angiolymphoid hyperplasia with eosinophilia – nodules of the head and neck; adults

Limited to Neonates or Infants

• Erythema toxicum neonatorum – papules and pustules with erythematous flare; neonates

• Incontinentia pigmenti (stages I and II) – linear streaks of vesicles and keratotic papules along Blaschko’s lines

• Infantile eosinophilic folliculitis – recurrent crops of pruritic follicular papules and pustules, primarily of the head and neck

PUPPP, pruritic urticarial papules and plaques of pregnancy.

Hypereosinophilic Syndrome

Classically defined as peripheral eosinophilia (>1500 eosinophils/microliter) for at least 6 months (or less than 6 months if associated end-organ damage), with multi-organ involvement, but in the absence of an identifiable cause (Table 20.2).

Divided into major forms: (1) myeloproliferative – characterized by specific mutations, in particular the FIP1L1PDGFRA fusion gene, male predominance, and endomyocardial disease; and (2) lymphocytic – characterized by a clonal proliferation of T cells, as detected by flow cytometry and T-cell receptor gene rearrangement, as well as increased production of Th2 cytokines, e.g. IL-5, which activates eosinophils.

Mucocutaneous lesions are seen in at least 50% of patients and include nonspecific pruritic erythematous papules and nodules, urticaria, angioedema, dermatitis, erythroderma, and in the myeloproliferative form, mouth or anogenital ulcers; thromboses can lead to retiform purpura.

DDx: with the exception of granuloma faciale and eosinophilic folliculitis, the entities outlined in Fig. 20.1; several of the entities in Table 20.1, in particular parasitic infections; hereditary and acquired angioedema; for lymphoproliferative form, cutaneous T-cell lymphoma; if oral ulcers, oral aphthae.

Rx: FIP1L1PDGFRA-positive myeloproliferative form – imatinib, other tyrosine kinase inhibitors (e.g. nilotinib); lymphoproliferative form – systemic CS ± mepolizumab (anti-IL-5 monoclonal antibody).

For further information see Ch. 25. From Dermatology, Third Edition.